Contineum Therapeutics, Inc.

The momentum for this stock is not very good. Contineum Therapeutics, Inc. is not a good value stock. Contineum Therapeutics, Inc. is not a good growth stock. Contineum Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Contineum Therapeutics, Inc..
Log in to see more information.
CTNM Fundamental Data by TradingView

News

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Business Wire Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways...\n more…

Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $32.00
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $32.00

Zolmax Contineum Therapeutics (NASDAQ:CTNM - Free Report) had its target price boosted by Royal Bank of Canada from $30.00 to $32.00 in a research note published on Wednesday morning, Benzinga reports. They...\n more…

Contineum Therapeutics (NASDAQ:CTNM) PT Raised to $32.00 at Royal Bank of Canada
Contineum Therapeutics (NASDAQ:CTNM) PT Raised to $32.00 at Royal Bank of Canada

Ticker Report Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) had its price target raised by Royal Bank of Canada from $30.00 to $32.00 in a research report issued on Wednesday, Benzinga reports. The...\n more…

Contineum Therapeutics (NASDAQ:CTNM) Issues Earnings Results
Contineum Therapeutics (NASDAQ:CTNM) Issues Earnings Results

Zolmax Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by...\n more…

Contineum Therapeutics (NASDAQ:CTNM) Stock Price Down 6.1%
Contineum Therapeutics (NASDAQ:CTNM) Stock Price Down 6.1%

Ticker Report Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) shares fell 6.1% during trading on Tuesday . The stock traded as low as $16.05 and last traded at $16.27. 16,490 shares traded hands...\n more…

CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024
CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCTNM stock results show that Contineum Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…